NASDAQ:OMEROmeros Stock Price, Forecast & News

$15.35

+0.58 (+3.93 %)

(As of 05/26/2020 04:00 PM ET)

Add

Compare

Today's Range

$14.68

Now: $15.35▼

$15.46

50-Day Range

$12.24

MA: $14.94▼

$16.99

52-Week Range

$8.50

Now: $15.35▼

$20.92

Volume274,800 shs

Average Volume706,287 shs

Market Capitalization$836.74 million

P/E RatioN/A

Dividend YieldN/A

Beta1.95

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that is in Phase III clinical trial for hematopoietic stem-cell transplant-associated thrombotic microangiopath, immunoglobulin A nephropathy, and atypical hemolytic uremic syndrome; and Phase II clinical trial to treat lupus nephritis and other renal diseases. Its clinical programs also consists of PDE10 (OMS824) which is in Phase II clinical trial for treating Huntington's disease and schizophrenia; PPAR? (OMS405) that is in Phase II clinical trial to treat opioid and nicotine addiction; and PDE7 (OMS527), which is in Phase I clinical trial for treating addiction and compulsive disorders, and movement disorders. In addition, the company's preclinical programs comprise MASP-3 (OMS906) for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders; MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Further, its preclinical programs include G protein-coupled receptor (GPCR) platform, including GPR174, GPR151, GPR161, and other Class A orphan GPCRs for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular (CV), musculoskeletal, and other disorders; and antibody platform for metabolic, CV, oncologic, musculoskeletal, and other disorders. The company was incorporated in 1994 and is based in Seattle, Washington.

Beat the Market (BTM) Rank^™

3.3 Analyst's Opinion

Consensus Rating
Omeros has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $25.33, Omeros has a potential upside of 65.0% from its current price of $15.35.
Amount of Analyst Coverage
Omeros has only been the subject of 3 research reports in the past 90 days.

3.0 Community Rank

Outperform Votes
Omeros has received 721 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Omeros has received 494 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Omeros has received 59.34% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Omeros and other stocks. Vote “Outperform” if you believe OMER will outperform the S&P 500 over the long term. Vote “Underperform” if you believe OMER will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Omeros does not currently pay a dividend.
Dividend Growth
Omeros does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Omeros insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $72,000.00 in company stock.
Percentage Held by Insiders
Only 11.30% of the stock of Omeros is held by insiders.
Percentage Held by Institutions
57.44% of the stock of Omeros is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Omeros are expected to decrease in the coming year, from ($1.40) to ($2.09) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Omeros is -8.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Omeros is -8.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Overall Beat the Market Rank^™

1.45 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryPharmaceuticals

SectorMedical

Current SymbolNASDAQ:OMER

Previous Symbol

CUSIP68214310

CIK1285819

Webwww.omeros.com

Phone206-676-5000

Debt

Debt-to-Equity RatioN/A

Current Ratio1.48

Quick Ratio1.46

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$111.81 million

Price / Sales7.48

Cash FlowN/A

Price / Cash FlowN/A

Book Value($2.19) per share

Price / Book-7.01

Profitability

EPS (Most Recent Fiscal Year)($0.96)

Net Income$-84,490,000.00

Net Margins-78.52%

Return on EquityN/A

Return on Assets-58.57%

Miscellaneous

Employees236

Outstanding Shares54,511,000

Market Cap$836.74 million

Next Earnings Date8/13/2020 (Estimated)

OptionableOptionable

Receive OMER News and Ratings via Email

Sign-up to receive the latest news and ratings for OMER and its competitors with MarketBeat's FREE daily newsletter.

Omeros (NASDAQ:OMER) Frequently Asked Questions

How has Omeros' stock been impacted by COVID-19 (Coronavirus)?

Omeros' stock was trading at $15.04 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, OMER shares have increased by 2.1% and is now trading at $15.35. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Omeros?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Omeros in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Omeros.

When is Omeros' next earnings date?

Omeros is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Omeros.

How were Omeros' earnings last quarter?

Omeros Co. (NASDAQ:OMER) released its quarterly earnings results on Monday, May, 11th. The biopharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by $0.19. The biopharmaceutical company earned $23.54 million during the quarter, compared to analyst estimates of $30.92 million. View Omeros' earnings history.

What price target have analysts set for OMER?

4 equities research analysts have issued twelve-month target prices for Omeros' shares. Their forecasts range from $17.00 to $34.00. On average, they anticipate Omeros' share price to reach $25.33 in the next twelve months. This suggests a possible upside of 65.0% from the stock's current price. View analysts' price targets for Omeros.

Has Omeros been receiving favorable news coverage?

News stories about OMER stock have trended very negative recently, InfoTrie reports. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Omeros earned a media sentiment score of -3.1 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutOmeros.

Who are some of Omeros' key competitors?

Some companies that are related to Omeros include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), AbbVie (ABBV), Allergan (AGN), Zoetis (ZTS), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX) and Corcept Therapeutics (CORT). View all competitors.

What other stocks do shareholders of Omeros own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Omeros investors own include ACADIA Pharmaceuticals (ACAD), Exelixis (EXEL), Array Biopharma (ARRY), Inovio Pharmaceuticals (INO), Sangamo Therapeutics (SGMO), Ocular Therapeutix (OCUL), Verastem (VSTM), Amarin (AMRN), Bausch Health Companies (BHC) and NVIDIA (NVDA).

Who are Omeros' key executives?

Omeros' management team includes the following people:

Dr. Gregory A. Demopulos, Co-Founder, Chairman, CEO & Pres (Age 60)
Mr. Michael A. Jacobsen, Chief Accounting Officer, VP of Fin. & Treasurer (Age 61)
Ms. Marcia S. Kelbon, VP of Patent, Gen. Counsel & Sec. (Age 59)
Dr. Pamela Pierce Palmer, Co-Founder (Age 56)
Dr. George A. Gaitanaris, Chief Scientific Officer & VP of Science (Age 62)

What is Omeros' stock symbol?

Omeros trades on the NASDAQ under the ticker symbol "OMER."

Who are Omeros' major shareholders?

Omeros' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.79%), Cormorant Asset Management LP (4.63%), State Street Corp (2.13%), Cpwm LLC (1.28%), UBS Group AG (0.93%) and Atom Investors LP (0.55%). Company insiders that own Omeros stock include Marcia S Kelbon and Thomas J Cable. View institutional ownership trends for Omeros.

Which institutional investors are selling Omeros stock?

OMER stock was sold by a variety of institutional investors in the last quarter, including Deutsche Bank AG, Morgan Stanley, Morgan Stanley, D.A. Davidson & CO., Tudor Investment Corp Et Al, Hohimer Wealth Management LLC, Cpwm LLC, and United Capital Financial Advisers LLC. View insider buying and selling activity for Omeros.

Which institutional investors are buying Omeros stock?

OMER stock was bought by a variety of institutional investors in the last quarter, including Cormorant Asset Management LP, BlackRock Inc., Atom Investors LP, State Street Corp, Two Sigma Investments LP, Trexquant Investment LP, Squarepoint Ops LLC, and Balyasny Asset Management LLC. View insider buying and selling activity for Omeros.

How do I buy shares of Omeros?

Shares of OMER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Omeros' stock price today?

One share of OMER stock can currently be purchased for approximately $15.35.

How big of a company is Omeros?

Omeros has a market capitalization of $836.74 million and generates $111.81 million in revenue each year. The biopharmaceutical company earns $-84,490,000.00 in net income (profit) each year or ($0.96) on an earnings per share basis. Omeros employs 236 workers across the globe.

What is Omeros' official website?

The official website for Omeros is www.omeros.com.

How can I contact Omeros?

Omeros' mailing address is 201 ELLIOT AVENUE WEST, SEATTLE WA, 98119. The biopharmaceutical company can be reached via phone at 206-676-5000.

This page was last updated on 5/26/2020 by MarketBeat.com Staff